A combination of tumor separation surgery and a high dose of hypofractionated stereotactic radiosurgery (SRS) or high-dose single-fraction SRS has been found to be safe and effective in controlling spinal metastases, according to a new study conducted by researchers at Memorial Sloan-Kettering Cancer Center.
This finding is fleshed out in the article "Local disease control for spinal metastases following 'separation surgery' and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. Clinical article," by Ilya Laufer, M.D., and colleagues, published today online in the Journal of Neurosurgery: Spine .
AdvertisementThe authors reviewed and analyzed data in the charts of 186 patients who presented with epidural spinal cord compression due to spinal metastases. All of these patients underwent tumor separation surgery to decompress the spinal cord and stabilize the spine sometime between 2002 and 2011. During this procedure the tumor was dissected away from the spinal cordor separatedproviding a space between the spinal dura and any remaining tumor. Unlike in traditional spinal tumor surgery, extensive tumor resection was not pursued to reduce surgical morbidity. The spine was also stabilized with screws and rods.
Within 2 to 4 weeks after surgery, stereotactic radiosurgery (SRS) was performed to deliver radiation to the remaining metastatic tumor without damaging the spinal cord. In 40 patients (21.5%) radiation was delivered in a single 24-Gray (Gy) dose to the tumor (high-dose single-fraction SRS). In 37 patients (19.9%) a median total dose of 27 Gy (range 24 to 30 Gy) was delivered in three fractions (high-dose hypofractionated SRS), and in 109 patients (58.6%) a median total dose of 30 Gy (range 18 to 36 Gy) was delivered in five or six fractions (low-dose hypofractionated SRS).
In their review and analysis, the authors identified the following:
- Better local tumor control in patients who underwent high-dose hypofractionated SRS than in those who underwent low-dose hypofractionated SRS.
- The 1-year cumulative local progression rates were 4.1% in the high-dose group and 22.6% in the latter group.
- The difference in tumor progression-free survival between these two groups was statistically significant.
- In the group of patients who underwent single-fraction SRS, the 1-year cumulative local progression rates was 9.0%.
- There was no statistically significant difference in tumor progression-free survival between this group and the high-dose hypofractionated SRS group.
- Other variables were examined to determine their effect on local tumor control, specifically individual patient characteristics, radiosensitivity of the metastatic tumor to conventional radiation, response to preoperative radiotherapy, grade of spinal cord compression, and extent of spinal cord decompression.
- None of these variables significantly correlated with progression-free survival.
- This lack of correlation confirms that the "tumor response to high-dose radiation is independent of these characteristics."
The authors begin their paper by stating the rationale behind treatment of metastatic spine tumors. Care "is palliative with the goal of improving or maintaining neurological function, achieving spine stability, relieving pain, and providing durable tumor control." The object is to make the patient as comfortable and neurologically functional as long as possible despite the presence of systemic disease. In this situation sometimes less surgery is better.
According to coauthor Dr. Mark Bilsky, "The strategy of separation surgery followed by high-dose hypofractionated or single-fraction radiation has revolutionized our ability to provide meaningful palliation for this very complicated patient population with metastatic spine tumors. This limited surgery consisting of spinal cord decompression and posterior segmental fixation is well tolerated and can be performed with limited morbidity. Instead of attempting gross total resection followed by conventional external beam radiation, separation surgery followed by SRS provides excellent durable tumor control of residual vertebral body tumors and even large paraspinal tumors, while minimizing the extent of surgical intervention. The integration and wide availability of SRS as a postoperative adjuvant following separation surgery will help shift treatment paradigms for metastatic spine tumors to ultimately provide better palliation for these patients."
P Integra Flowable Wound Matrix Device Gets European CE Mark Certification Study Sheds More Light on Role Played by Her2 Cancer Gene in Spread of Breast Cancer M
You May Also Like